Reckitt Benckiser Group plc (OTCMKTS:RBGLY) Receives Average Rating of “Hold” from Analysts

Reckitt Benckiser Group plc (OTCMKTS:RBGLY) has earned an average recommendation of “Hold” from the seven ratings firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $5,400.00.

Separately, JPMorgan Chase & Co. lowered Reckitt Benckiser Group from an “overweight” rating to a “neutral” rating in a research report on Thursday, August 29th.

Reckitt Benckiser Group Price Performance

Shares of OTCMKTS RBGLY opened at $11.56 on Thursday. Reckitt Benckiser Group has a 1 year low of $10.24 and a 1 year high of $15.03. The firm has a 50-day moving average of $11.10 and a 200 day moving average of $11.51.

Reckitt Benckiser Group Cuts Dividend

The business also recently announced a dividend, which will be paid on Monday, September 23rd. Investors of record on Monday, August 5th will be given a dividend of $0.1915 per share. The ex-dividend date is Monday, August 5th.

Reckitt Benckiser Group Company Profile

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.